Owlet Inc Stock Price, News & Analysis

Owlet (NYSE: OWLT) will report third quarter 2025 financial results after market close on Thursday, November 13, 2025. The company said President & CEO Jonathan Harris and CFO Amanda Twede Crawford will host a conference call at 4:30 p.m. ET the same day to discuss results and provide a business update.

Participants can join by phone at 833-470-1428 (domestic) or 646-844-6383 (international) using Access Code 428622. A simultaneous webcast and replay will be available in the Events section of Owlet's Investor Relations website at investors.owletcare.com.

Owlet (NYSE: OWLT) priced an underwritten public offering of 4,196,000 shares of Class A common stock at $7.15 per share, with gross proceeds expected to be approximately $30.0 million.

The company granted underwriters a 30‑day option to purchase up to an additional 629,400 shares at the public offering price less underwriting discounts and commissions. The offering is expected to close on or about October 23, 2025, subject to customary closing conditions.

Owlet intends to use net proceeds to support continued commercialization, research and development, and general corporate purposes. William Blair and TD Cowen are joint bookrunners; Craig‑Hallum is co‑manager. The offering is made pursuant to an effective Form S‑3 registration statement.

Owlet (NYSE: OWLT) announced a proposed underwritten public offering of its Class A common stock on October 21, 2025. The company said it will grant underwriters a 30-day option to buy up to 15% additional shares at the offering price less underwriting discounts and commissions. All shares are being offered by Owlet, with net proceeds intended to support continued commercialization, research and development, and general corporate purposes.

William Blair and TD Cowen are joint bookrunners and Craig-Hallum is co-manager. The offering is subject to market conditions and will be made by prospectus supplement filed under Owlet’s effective Form S-3 (File No. 333-281556). Prospective investors can obtain the preliminary prospectus supplement from the underwriters or the SEC website.

Owlet (NYSE: OWLT) received CDSCO approval to distribute Dream Sock in India and plans a broader launch of Dream Sock, Dream Sight and Dream Duo in early 2026. The company says its wearable Dream Sock monitors oxygen and pulse for infants 0–18 months (2.5–13.6 kg) and pairs with the Dream App and Base Station for real-time alerts. Owlet noted India’s large birth cohort (~23 million babies expected in 2025), >80% urban smartphone penetration, and that its products are already used by 2 million families in 30+ countries.

Owlet (NYSE: OWLT) announced that on September 30, 2025 its Compensation Committee approved an equity inducement award for Jordan Thompson, Vice President and Corporate Controller, in connection with his hiring. The award consists of 129,863 restricted stock units (Inducement RSUs). Vesting: 33.33% on May 15, 2026, then the remainder in equal quarterly installments through May 15, 2028, subject to continued employment. The Committee approved the award using the NYSE employment inducement exemption under Rule 303A.08, so shareholder approval was not required.

Owlet (NYSE: OWLT) has announced a proposed settlement of stockholder derivative litigation. The settlement, detailed in a Stipulation dated April 2, 2025, requires Owlet to implement corporate governance reforms and internal controls. The settlement hearing is scheduled for February 6, 2026, at the U.S. District Court for the Central District of California.

As part of the settlement, Plaintiffs' Counsel is requesting $675,000 in attorneys' fees and expenses, which Defendants have agreed not to oppose. Current Owlet stockholders as of April 2, 2025, have the right to object to the settlement by filing written objections at least 14 days before the settlement hearing.

Owlet (NYSE:OWLT) has launched its new Dream Sight™ HD video baby monitor and next-generation Dream Duo™ system. The Dream Sight, priced at $99.99, features 2K HD resolution, motion detection, two-way talk capabilities, and 256-bit encryption. It can be used standalone or integrated with the FDA-cleared Dream Sock.

The premium Dream Duo bundle, retailing at $379.99, combines Dream Sight with the medically-certified Dream Sock, which monitors baby's oxygen level, pulse rate, and sleep trends. Clinical data shows 96% of parents report reduced anxiety and 94% experience better sleep using Owlet products.

The products are available in the U.S., Canada, the UK, and Europe through major retailers including Amazon, Target, and Walmart.

Owlet (NYSE: OWLT) has announced the expansion of its medically-certified Dream Sock™ into South Africa, marking its presence across three continents including North America, Europe, and Africa. The Dream Sock, distributed as a Class C Medical Device with CE Marking, is designed for babies aged 0-18 months and monitors vital signs including pulse rate, oxygen level, and sleep patterns.

The device connects to the Owlet Dream App and Base Station, providing real-time health notifications to parents. The system includes Predictive Sleep Technology and can be paired with Owlet Cam® 2 for comprehensive monitoring. The product is NAPPI coded for medical aid reimbursement and available through major retailers in South Africa.

Owlet (NYSE: OWLT) has announced the expansion of its medically-certified Dream Sock™ to South Africa, marking its presence across three continents - North America, Europe, and Africa. The Dream Sock™, distributed as a Class C Medical Device with CE Marking, is designed for babies aged 0-18 months and monitors vital signs including pulse rate, oxygen level, and sleep patterns.

The device connects to the Owlet Dream App and Base Station, providing real-time health notifications to parents. The product features Predictive Sleep Technology and can be paired with Owlet Cam® 2 as part of the Dream Duo™ package. The Dream Sock is NAPPI coded, making it eligible for medical aid reimbursement when purchased through healthcare providers in South Africa.